

Cleveland Clinic | ASCO 2024
Friday, May 31st

Time	Title	Session	Abstract/ Poster Number	Location
3:09 PM CDT	Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft	6502	S100bc
4:45 PM CDT	NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)	Lung Cancer—Non-Small Cell Metastatic	8506	Arie Crown Theater

Saturday, June 1st

Time	Title	Session	Abstract/ Poster Number	Location
8:12 AM CDT	A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.	Genitourinary Cancer—Kidney and Bladder	4512	S100bc
9:00 AM – 12:00 PM CDT	Targeting glioma stem cells with thyroid hormone suppression: Phase 1/2 trial of methimazole in patients with progressive grade 4 gliomas.	Central Nervous System Tumors	2044 / 343	Hall A
9:00 AM – 12:00 PM CDT	Study of ELU001, a C'Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	TPS3173 / 311b	Hall A
9:00 AM – 12:00 PM CDT	A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).	Central Nervous System Tumors	2072 / 371	Hall A
9:00 AM – 12:00 PM CDT	IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors.	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	TPS3186 / 318a	Hall A

9:00 AM – 12:00 PM CDT	A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	TPS3180 / 315a	Hall A
9:00 AM – 12:00 PM CDT	Establishing a protocol to increase racial/ethnic minority enrollment on an active radiation oncology randomized clinical trial.	Care Delivery/Models of Care	TPS1638 / 509a	Hall A
9:00 AM – 12:00 PM CDT	Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting.	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	3159 / 304	Hall A
9:00 AM – 12:00 PM CDT	Can immune therapy prevent pre-clinical cancer from progression? The impact of immune therapy on secondary cancer incidence.	Developmental Therapeutics—Immunotherapy	2651 / 130	Hall A
9:00 AM – 12:00 PM CDT	Association between social determinants of health and time to treatment for newly diagnosed multiple myeloma.	Care Delivery/Models of Care	1583 / 454	Hall A
9:00 AM – 12:00 PM CDT	Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors.	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	3027 / 172	Hall A
9:00 AM – 12:00 PM CDT	Novel method (MAXIM) uses deep learning model to impute missing stains in multiplex images (mIF).	Developmental Therapeutics—Immunotherapy	2580 / 59	Hall A
9:00 AM – 12:00 PM CDT	A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.	Developmental Therapeutics—Immunotherapy	2598 / 77	Hall A
9:00 AM – 12:00 PM CDT	A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.	Developmental Therapeutics—Immunotherapy	TPS2684 / 155b	Hall A

9:00 AM – 12:00 PM CDT	Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study.	Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology	3105 / 250	Hall A
9:00 AM – 12:00 PM CDT	A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR).	Central Nervous System Tumors	TPS2089 / 388a	Hall A
9:00 AM – 12:00 PM CDT	A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).	Central Nervous System Tumors	TPS2099 / 393a	Hall A
9:00 AM – 12:00 PM CDT	The immunological milieu of oropharyngeal squamous cell carcinoma (OPC) according to HPV and smoking status and its influence on prognosis.	Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology	3147 / 292	Hall A
9:00 AM – 12:00 PM CDT	A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.	Developmental Therapeutics— Immunotherapy	TPS2682 / 154b	Hall A
9:00 AM – 12:00 PM CDT	Clinical utility and accessibility of functional precision medicine for relapsed/refractory pediatric and adult cancers.	Care Delivery/Models of Care	1551 / 422	Hall A
9:00 AM – 12:00 PM CDT	Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.	Developmental Therapeutics— Immunotherapy	2542 / 21	Hall A
9:00 AM – 12:00 PM CDT	A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).	Central Nervous System Tumors	TPS2101 / 394a	Hall A
1:45 PM – 2:00 PM CDT	Understanding New Strategies to Prevent and Manage Chronic Graft-Versus-Host Disease	Hematopoietic Stem Cell Transplantation: Exploring the Latest Advances	-	E450b

1:30 PM – 4:30 PM CDT	Primary immunotherapy monotherapy (PRIMO) in locally advanced cutaneous squamous cell carcinoma.	Melanoma/Skin Cancers	9585 / 369	Hall A
1:30 PM – 4:30 PM CDT	DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.	Sarcoma	TPS1158 7 / 512b	Hall A
1:30 PM – 4:30 PM CDT	Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.	Sarcoma	TPS1159 0 / 514a	Hall A
3:12 PM CDT	Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women.	Prevention, Risk Reduction, and Genetics	10501	S100a
4:00 PM CDT	Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.	Prevention, Risk Reduction, and Genetics	10503	S100a
5:00 PM CDT	Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	7006	S100bc
Sunday, June 2nd				
Time	Title	Session	Abstract/ Poster Number	Location
9:00 AM – 12:00 PM CDT	Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.	Genitourinary Cancer—Kidney and Bladder	4589 / 284	Hall A
9:00 AM – 12:00 PM CDT	Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5).	Genitourinary Cancer—Kidney and Bladder	4570 / 265	Hall A

9:00 AM – 12:00 PM CDT	Neoadjuvant immunotherapy for oropharynx cancer: Correlative studies and long-term outcomes from the CIAO trial.	Head and Neck Cancer	6059 / 375	Hall A
9:00 AM – 12:00 PM CDT	An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).	Breast Cancer— Metastatic	TPS1122 / 99a	Hall A
9:00 AM – 12:00 PM CDT	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes.	Genitourinary Cancer—Kidney and Bladder	4567 / 262	Hall A
9:00 AM – 12:00 PM CDT	Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.	Breast Cancer— Local/Regional/Adju vant	567 / 159	Hall A
9:00 AM – 12:00 PM CDT	Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB).	Genitourinary Cancer—Kidney and Bladder	4520 / 215	Hall A
9:00 AM – 12:00 PM CDT	Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.	Head and Neck Cancer	TPS6116 / 430b	Hall A
9:00 AM – 12:00 PM CDT	Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH).	Genitourinary Cancer—Kidney and Bladder	4580 / 275	Hall A
9:00 AM – 12:00 PM CDT	Association of artificial intelligence–derived collagen disorder architecture (CoDA) features with survival outcome and objective response to immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma.	Head and Neck Cancer	6061 / 377	Hall A

9:00 AM – 12:00 PM CDT	Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial.	Head and Neck Cancer	6104 / 420	Hall A
9:00 AM – 12:00 PM CDT	FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.	Genitourinary Cancer—Kidney and Bladder	4588 / 283	Hall A
9:00 AM – 12:00 PM CDT	Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.	Genitourinary Cancer—Kidney and Bladder	4566 / 261	Hall A
9:00 AM – 12:00 PM CDT	A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC.	Head and Neck Cancer	6038 / 341	Hall A
9:00 AM – 12:00 PM CDT	Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39.	Genitourinary Cancer—Kidney and Bladder	4562 / 257	Hall A
9:00 AM – 12:00 PM CDT	Comparing treatment modalities for T2N0M0 muscle invasive bladder cancer: A propensity score analysis with the National Cancer Database.	Genitourinary Cancer—Kidney and Bladder	4604 / 299	Hall A
9:00 AM – 12:00 PM CDT	Dissecting the significance of ACP1 gene alterations in prostate cancer (PCa).	Genitourinary Cancer—Prostate, Testicular, and Penile	5025 / 321	Hall A
9:00 AM – 12:00 PM CDT	Independent blinded validation of an AI-based digital histology classifier for prostate cancer recurrence and metastasis risk prediction.	Genitourinary Cancer—Prostate, Testicular, and Penile	5098 / 504	Hall A
9:00 AM – 12:00 PM CDT	Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).	Breast Cancer— Metastatic	1071 / 49	Hall A

9:00 AM – 12:00 PM CDT	Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.	Genitourinary Cancer—Prostate, Testicular, and Penile	5081 / 487	Hall A
9:00 AM – 12:00 PM CDT	Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.	Genitourinary Cancer—Kidney and Bladder	4563 / 258	Hall A
9:00 AM – 12:00 PM CDT	Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?	Breast Cancer—Metastatic	1039 / 17	Hall A
11:36 AM CDT	Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe).	Central Nervous System Tumors	2014	E350
12:00 PM CDT	Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).	Central Nervous System Tumors	2106	E350
12:12 PM CDT	Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.	Central Nervous System Tumors	2018	E350
4:36 PM CDT	Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR).	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	7010	E450b
Monday, June 3rd				
Time	Title	Session	Abstract/Poster Number	Location
8:12 AM CDT	Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).	Genitourinary Cancer—Kidney and Bladder	4502	Hall B1

9:00 AM – 12:00 PM CDT	Neuropathy trajectory informed by algorithm-based alerts from remote symptom monitoring (RSM) tool in breast cancer practice.	Quality Care/Health Services Research	11114 / 309	Hall A
9:00 AM – 12:00 PM CDT	Second primary B-ALL after exposure to lenalidomide for multiple myeloma: A US multicenter study.	Hematologic Malignancies— Plasma Cell Dyscrasia	7533 / 170	Hall A
9:00 AM – 12:00 PM CDT	A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft	TPS6590 / 146b	Hall A
9:00 AM – 12:00 PM CDT	Meta-analysis of mutational site-specificity and concordance/discordance characteristics of myeloid sarcoma.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft	6583 / 142	Hall A
9:00 AM – 12:00 PM CDT	A phase 1b/2 study of pivekimab sunirine (PVEK, IMG632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft	TPS6585 / 144a	Hall A
9:00 AM – 12:00 PM CDT	Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study.	Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia	7069 / 32	Hall A
9:00 AM – 12:00 PM CDT	Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).	Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia	7026 / 9	Hall A
9:00 AM – 12:00 PM CDT	Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft	6571 / 130	Hall A
9:00 AM – 12:00 PM CDT	Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.	Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia	TPS7085 / 67a	Hall A

9:00 AM – 12:00 PM CDT	Outcomes of blast-phase MPN and JAK2, MPL, and CALR mutated de novo AML: A propensity score-adjusted cohort study.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant	6526 / 85	Hall A
9:00 AM – 12:00 PM CDT	Mutation profiles and outcomes of patients with acute myeloid leukemia with autoimmune disease.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant	6536 / 95	Hall A
9:00 AM – 12:00 PM CDT	Access to palliative care in patients with multiple myeloma in the USA: A National Cancer Database (NCDB) analysis of years 2004-2020.	Hematologic Malignancies— Plasma Cell Dyscrasia	7563 / 200	Hall A
9:00 AM – 12:00 PM CDT	Therapy-related myeloid neoplasm risk score (TMNRS): A convenient clinical score for TMN risk assessment at presentation in adult patients (pts) with cancer.	Quality Care/Health Services Research	11164 / 359	Hall A
9:00 AM – 12:00 PM CDT	Domain-based analysis of RUNX1 somatic mutations in myeloid neoplasms.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant	6542 / 101	Hall A
9:00 AM – 12:00 PM CDT	Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL).	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant	TPS6589 / 146a	Hall A
9:00 AM – 12:00 PM CDT	Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant	TPS6593 / 148a	Hall A
9:00 AM – 12:00 PM CDT	Implementation of standardized electronic documentation of goals of care discussions to improve cancer care.	Quality Care/Health Services Research	11127 / 322	Hall A
10:21 AM CDT	Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma.	Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary	4016	E451
12:00 PM CDT	Racial differences in genomic profiles and targeted treatment use in ER+ HER2-metastatic breast cancer.	Breast Cancer— Metastatic	1017	Hall D1

1:30 PM CDT	Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.	Developmental Therapeutics— Immunotherapy	2506	Hall D2
1:30 PM – 4:30 PM CDT	Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy.	Lung Cancer—Non- Small Cell Metastatic	8611 / 475	Hall A
1:30 PM – 4:30 PM CDT	Cancer burden in South Asians in the United States: Epidemiologic report using Surveillance, Epidemiology, and End Results (SEER) program.	Prevention, Risk Reduction, and Genetics	10574 / 101	Hall A
1:30 PM – 4:30 PM CDT	Utility of a collaborative hematology oncology (HO) podcast series for post-ASCO updates and teaching critical appraisal.	Medical Education and Professional Development	9024 / 13	Hall A
1:30 PM – 4:30 PM CDT	Prevalence of pathogenic genetic variants in patients with gastric cancer ascertained through multi-gene panel testing.	Prevention, Risk Reduction, and Genetics	10578 / 105	Hall A
1:30 PM – 4:30 PM CDT	Cardiac and mortality outcomes in patients with breast cancer undergoing trastuzumab-based therapies.	Symptom Science and Palliative Care	12027 / 156	Hall A
1:30 PM – 4:30 PM CDT	Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study.	Lung Cancer—Non- Small Cell Local- Regional/Small Cell/Other Thoracic Cancers	8096 / 358	Hall A
1:30 PM – 4:30 PM CDT	Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.	Lung Cancer—Non- Small Cell Local- Regional/Small Cell/Other Thoracic Cancers	TPS8128 / 383b	Hall A
1:30 PM – 4:30 PM CDT	Integration of a focused podcast curriculum (PC) to improve hematology oncology fellow (HOF) knowledge: A multi-center cluster randomized controlled trial.	Medical Education and Professional Development	9041 / 30	Hall A
4:12 PM CDT	Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.	Breast Cancer— Local/Regional/Adju vant	504	Hall B1

5:24 PM CDT	Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.	Hematologic Malignancies— Plasma Cell Dyscrasia	7508	Hall D1
Tuesday, June 4th				
Time	Title	Session	Abstract/ Poster Number	Location
10:21 AM CDT	Assessing the prognostic value of transcriptomic data in multiple myeloma through machine learning methodologies.	Hematologic Malignancies— Plasma Cell Dyscrasia	7513	S102
11:09 AM CDT	HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.	Head and Neck Cancer	6005	S100a